chlorthalidone has been researched along with Water-Electrolyte Imbalance in 4 studies
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.
Water-Electrolyte Imbalance: Disturbances in the body's WATER-ELECTROLYTE BALANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In CKD stage 4-5 KDIGO without renal replacement therapy, bumetanide in combination with chlorthalidone is more effective in treating volume overload and hypertension than bumetanide with placebo." | 9.51 | Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial. ( Cabrera-Barron, R; Chida-Romero, JA; Dehesa-López, E; Madero, M; Martin-Alemañy, G; Perez-Navarro, LM; Solis-Jimenez, F; Valdez-Ortiz, R, 2022) |
| "In CKD stage 4-5 KDIGO without renal replacement therapy, bumetanide in combination with chlorthalidone is more effective in treating volume overload and hypertension than bumetanide with placebo." | 5.51 | Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial. ( Cabrera-Barron, R; Chida-Romero, JA; Dehesa-López, E; Madero, M; Martin-Alemañy, G; Perez-Navarro, LM; Solis-Jimenez, F; Valdez-Ortiz, R, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rosenberg, K | 1 |
| Solis-Jimenez, F | 1 |
| Perez-Navarro, LM | 1 |
| Cabrera-Barron, R | 1 |
| Chida-Romero, JA | 1 |
| Martin-Alemañy, G | 1 |
| Dehesa-López, E | 1 |
| Madero, M | 1 |
| Valdez-Ortiz, R | 1 |
| García-Blas, S | 1 |
| Bonanad, C | 1 |
| Llàcer, P | 1 |
| Ventura, S | 1 |
| Núñez, JM | 1 |
| Sánchez, R | 1 |
| Chamorro, C | 1 |
| Fácila, L | 1 |
| de la Espriella, R | 1 |
| Vaquer, JM | 1 |
| Cordero, A | 1 |
| Roqué, M | 1 |
| Ortiz, V | 1 |
| Racugno, P | 1 |
| Bodí, V | 1 |
| Valero, E | 1 |
| Santas, E | 1 |
| Moreno, MDC | 1 |
| Miñana, G | 1 |
| Carratalá, A | 1 |
| Bondanza, L | 1 |
| Payá, A | 1 |
| Cardells, I | 1 |
| Heredia, R | 1 |
| Pellicer, M | 1 |
| Valls, G | 1 |
| Palau, P | 1 |
| Bosch, MJ | 1 |
| Raso, R | 1 |
| Sánchez, A | 1 |
| Bertomeu-González, V | 1 |
| Bertomeu-Martínez, V | 1 |
| Montagud-Balaguer, V | 1 |
| Albiach-Montañana, C | 1 |
| Pendás-Meneau, J | 1 |
| Marcaida, G | 1 |
| Cervantes-García, S | 1 |
| San Antonio, R | 1 |
| de Mingo, E | 1 |
| Chorro, FJ | 1 |
| Sanchis, J | 1 |
| Núñez, J | 1 |
| Bowman, CA | 1 |
| Jeffcoate, WJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial[NCT03923933] | Phase 2 | 34 participants (Actual) | Interventional | 2019-06-18 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -3.4 |
| Treatment Grup | -13.5 |
Decrease in extracellular water measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|---|
| Placebo | -0.15 |
| Treatment Grup | 2.55 |
Decrease in extracellular water / total body water ratio measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of ECW/TBW (Mean) |
|---|---|
| Placebo | -0.24 |
| Treatment Grup | -2.92 |
decrease in blood pressure compared wit baseline measure (mmhg) (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -5.4 |
| Treatment Grup | -18.1 |
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -10 |
| Treatment Grup | -26.1 |
Increase in the fractional excretion of sodium compared with the baseline measure (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of sodium excreted (Mean) |
|---|---|
| Placebo | -0.348 |
| Treatment Grup | 0.598 |
Measured by bioelectrical impedance analysis, compared to the initial measurement (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|---|
| Placebo | -0.075 |
| Treatment Grup | -4.36 |
2 trials available for chlorthalidone and Water-Electrolyte Imbalance
| Article | Year |
|---|---|
Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial.
Topics: Aged; Bumetanide; Chlorthalidone; Humans; Hypertension; Middle Aged; Renal Insufficiency, Chronic; R | 2022 |
Diuretic Strategies in Acute Heart Failure and Renal Dysfunction: Conventional vs Carbohydrate Antigen 125-guided Strategy. Clinical Trial Design.
Topics: Acetazolamide; Acute Disease; CA-125 Antigen; Cardio-Renal Syndrome; Chlorthalidone; Creatinine; Diu | 2017 |
2 other studies available for chlorthalidone and Water-Electrolyte Imbalance
| Article | Year |
|---|---|
Electrolyte Disorders Common in Thiazide Diuretic Users.
Topics: Chlorthalidone; Cross-Sectional Studies; Humans; Hypokalemia; Hyponatremia; Sodium Chloride Symporte | 2022 |
Severe salt and water deficiency associated with a combination of atenolol and chlorthalidone.
Topics: Aged; Atenolol; Chlorthalidone; Drug Combinations; Female; Humans; Water-Electrolyte Imbalance | 1988 |